How to Cite
V, B., & N, A. (2021). Enhancement of solubility and bioavailability of poorly water-soluble drug. *Journal of Integral Sciences*, *4*(3), 01-19. Retrieved from https://jisciences.com/index.php/journal/article/view/34

Enhancement of solubility and bioavailability of poorly water-soluble drug

V. Bhagyavathi[1], N.Asha[2]

1. Research Student, St. Mary's College of Pharmacy, Chebrolu, Guntur-A.P-522 202
2. Assistant Professor, St. Mary's College of Pharmacy, Chebrolu, Guntur-A.P-522 202

Manuscript Submitted: 22-06-2021 Manuscript Revised: 04-07-2021 Manuscript Accepted 16-08-2021

ABSTRACT:-

More specifically, this work aims to investigate the cyclodextrin's complexation, solubility, dissolution rate, and efficacy in pharmaceutical formulations. The pharmacokinetic properties of cyclodextrin forms were also investigated. It's possible to increase the solubility of drug using cyclodextrine, demon strategic use of the term "solubility constant" to describe the effect on Lercin-3xtrin shows that the drug increases its phase solubility. It had a β-extrin concentration of 164.557 units per milliliter (eβ-extrin). The FT-IR studies demonstrated that all the ingredients used in making Lercanipariq included tablets were acceptable to immediate release. The dissolution of Lercidin became evident by Kneading inclusion test from complex LK2 was found to be greater than the pure substance or those made by other methods. The Lercandipine prepared with the inclusion complex system Kneading method, as well as tablets formulation F6 (F6 using Lercinium inclusion complex and Lanpirin 2% ingredients), failed to show any effect on physical appearance, drug content, and dissolution in short-character stability and profile tests. Thus, by solubilizing and thus enhancing, the lipid solubility, β-cyclodextrin has been shown to facilitate the release of Lercanipine.

Keywords: β-extrin, FT-IR, Lercandipine, β-cyclodextrin.

Introduction:-

The Immediate release formulation design includes any use of galenics which does not appreciably, or intentionally, increase the rate of drug release from the formulation or absorption. Most of the time, immediate release is obtained by using a dilution or formulation that doesn't take place; however, in some cases, prolonged

release or absorption may be a suitable. Drug formulations designed to release over time but which cannot be controlled, prolonged, and which also excludes sustained-release formulations

release refers to the giving of the drug into the gastrointestinal tract, tissue, and it includes the “presentation”; “circulation” refers to the movement of the drug outside the gastrointestinal tract and into the body During the guttissue release, the release is performed at a pH between 1 and 3, with particularity of 1 to 3, or typically at about pH 1. the formulaton of (as described above) or an acid can enable drug to be released in crystalline form has a pH of 1 to 3 or releases the drug as described herein at a formulation with a compound of formula (I), or an acid salt thereof Often the formulations of the invention release at least 80% (preferably at least 90%) of their active ingredient in a 70% (or above) potency, as stated above, such as in 1.5 hours, such as in two hours, or faster, than stated above, or above, 1.6% 1.7 hours or faster, and above, as stated above

Desired criteria for immediate release drug delivery system

When it is in a solid form that dissolves quickly, it should dissolve or break down in the stomach.

1. It should have a pleasant taste to mask the taste of liquid medications.
2. Don't worry about fragile parts.
3. You should make your mouth feel good when drinking it.
4. This product should not leave a trace in the mouth after it is swallowed.
5. So keep your dryness under control. Also, keep the temperature as low as possible.
6. It is mass-produced and can be made using the most standard methods and equipment.
7. The rapid disintegration and speedy excretion of the drug, allowing it to hit the blood stream and effect quickly.

A brief Introduction to Importance of Improving the Aqueous Solubility of Poorly Soluble Drugs.

Although it is easier, less costly, and more accurate to administer in this fashion, solid oral preparations have several advantages over other dosage forms, such as a higher stability. Contrary to popular belief, only the poorly water-soluble drugs don't tend to be absorbed after ingestion. The disuse of any of these drugs results in a loss of efficiency. Hence, the improvement of solubility is essential for improving oral delivery.

Drugs with good parenterally absorbed drugs show solubility in gastric juice and absorb solely when solute- or solvent-soluble. drug solubility and dissolution properties A major problem for formulation scientists is formulation solubility, which

varies throughout the pharmaceutical development process. Solid dispersion, dissolution, deposition, and micronization are three common approaches for improving drug solubility. Some strategies have advantages and drawbacks. Many techniques, including coordination with co-polymerization, have been employed to improve the water solubility of poorly water-soluble drugs

STUDIES ON SOLUBILITY IMPROVEMENT:

Dosage forms must be able to ensure that the desired pharmacological response is achieved. the drug potency of extravasation is proportional to the amount administered intravenously However, if the pharmacological effects of the drug are mediated through the blood, then the rate of absorption is critical as it dictates the plasma concentration peak and the duration of the plasma concentration period. bioavailability: thus, the quantity of the active agent that can be delivered to the blood is referred to as "bioavailability"

Methods Used For Increasing the Dissolution Rate of Poorly Soluble Drugs:

A drug with low solubility and/slow rate of dissolution in the biological fluids is classified as poorly bioavailable.

1. At physiologic pH, the dissolved drug has limited stability.
2. Inadequate partition coefficient, as well as permeation problems due to biomembrane and thus low distribution capacity.
3. significantly overactive metabolisms

Some possible causes of bioavailability problems include:

1. **The Pharmaceutical Approach** also called generics are generic formulations that aren't structurally identical to name-brand formulations, used to make low-cost generic drugs, which modify these elements without changing their chemical structure.
2. **The Pharmacokinetic Approach** in the way drugs' chemical structure is altered can change their pharmacokinetics
3. **The Biological Approach** one approach may be taken from a fluid to a nonfluid or changing from oral to intravenous to subcutaneous route.

Secondly, chemical structure modification is far more expensive and time-consuming than using pharmacophoreansmics. Esprits, transformations, processes that the drug must undergo in order to increase dissolution rate, or its physicochemical properties, are all included in the formulation and production process.

Approaches to improve the solubility or to increase the available surface area for dissolution:

Elevation of drug solubility or dissolution rate may be accomplished in various ways. Simple techniques can be described briefly.

1. Micronization: Agitation is commonly used to reduce the size of the solid drug particles to about 1 microns (fluid energy or jet mill). The final step in the processing is also known as micro-milling. Drugs that have been micronized to allow for higher bioavailability include griseofulvins and many steroidal and sulpha drugs.

2. Nanonisation: In the novel process, the powder is reduced to amphoteric nanocrystals of size 200 – 600 nm Currently, the most commonly used processes produce drug-dispoweddle complexes as a dispersion of water-soluble crystals (called nanosuspension). Three basic technologies have been identified to use in this day and age to enhance nanoparticle yields: immersion, spray, and s-drying.

Pearl milling

i. Homogenisation in water (wet milling as in a colloid mill)

ii. For drop casting, non-likelyeus-based or water-dispersistent media, homogenization

3. Supercritical Fluid Recrystallization: Another novel solubilization method that has seen some applications recently is SCF-adjuvanced particle size reduction. A supercritical fluid (e.g. carbon dioxide) will assume the properties of both a liquid and a gas if its temperature and pressure are above its critical values (Ts and Pv). Since SCFs are quite compressible, this fluid's density and mass flow are easily influenced by pressure changes and will lead to substantial changes in its solvent power. SCF recrystallises the crystals and uses them as part of the recrystallization procedure.

4. Use of Surfactants: Surfactants are highly useful as penetration aids and as well as carriers. In granulated suspension, they enhance the dissolution fluid's wetting and penetration ability primarily by promoting wetting of the solid drug particles. Above their critical micelle concentration (CMC), the drug is not absorbed in the dissolution fluid; it is retained within the micelle structure. The majority of non-polar surfactants like polysorbates are non-ionic. An agent may be useful in increasing the bioavailability of other medications if it is added to the formulation and it's been shown to be excreted more efficiently by the body.

5. Use of Salt Forms: Salts have a greater solubility and soluability over time Generally, it is believed that the differences between the pKas of the group and the counterion should be 3 units for the formation of stable salts Water-soluble alkali and water-soluble basic drugs like atropine and atropin salts are less water-soluble than their respective salt drugs. The physical and chemical properties of the salt and therapeutic indications are important factors for salt selection.

Salt formation does have its **limitations** –

- Neutral compounds cannot be formed.

- A weak base can be hard to crystallise into salts, and an acid can be impossible to crystallise.
- The salt may be hygroscopic, exhibit polymorphism or has poor processing characteristics.
- In the final phase of conversion of the drug's salt to free acid or base on the surface of the solid dosage form, we inhibit or delay drug release.
- Low solubility of precipitated drug in the GI fluid medium

Use of Precipitation Inhibitors: When free concentration increases above the solubility point, the resulting supersaturation (moisturensituation) will result in precipitation or crystallisation. This can be prevented using only by non-flammable polymers such as HPMC, EVOH, EVA, etc.

- Reduce the crystallisation rate by increasing the viscosity of the crystals
- Use steric hindrance to protect drug molecules from crystallisation while they are forming crystals, and for those crystals that are already formed, keep it from separating by interfering with intermolecular interactions.
- Produce an insoluble product and cover the crystal faces of the host.

6. Alteration of pH of the Drug Microenvironment: One method is to form the tablets in situ, using a buffer; the other is to add buffers to the formulation, such as buffered tablets.

7. Use of Amorphs, Anhydrates, Solvates and Metastable Polymorphs: Drug delivery system form depends on the nature of the solid structure of the drug; better solubility is important. Amorphs are more soluble than metastable polymorphs, anhydrates are more soluble than other metastable materials, and hydrates are more soluble than amorphous materials, as well as solubilicate than non-solutes.

8. Solvent Deposition: Aqueous solvent like nifediol is used to extract the drug residue from the hydrophobic drug product, for example, and then deposited on an insoluble, hydrophilic, hydrophilic polymer like starch or microcrystalline cellulose via simple evaporation.

9. Precipitation: In this method, the poorly water-soluble drug is dissolved and then followed by the precipitation of the drug into nanoparticles via a non-water phase such as glycerol. Also known as hydros, this product is a viscous (thick and fluid)

10. Selective Adsorption on Insoluble Carriers: Enriching solutions that dissolve poorly, such as indomethacater and prednisone, by sustaining a high concentration gradient is advantageous for those drugs that are water-soluble. The two reasons suggested for the rapid release of adsorbate drug from clays include: weak bonding,

which allows the drug to flow easily in the aqueous medium, and the fact that the medium itself is already absorbed.

Methods :-

Formulation Studies for Inclusion Complexes:

Phase solubility studies:

Phase solubility studies for Lercanidipine complexes were performed to determine how the complexes of cyclodextrin affect the solubility of the Lercanidipine. These studies also determine the stoichiometry of drug: cyclodextrin complexes and numerical values of their stability constants.

Phase solubility of Lercanidipine with β-cyclodextrin.

Procedure: For phase solubility studies of Lercanidipine, an excess of drug was added to 20 ml portions of distilled water, each containing variable amount of cyclodextrin such as 0, 1, 3, 6, 9, 12, and 15 x 10-3 moles/liter (mM). All the above solutions with variable amount of cyclodextrins were shaken for 24 hours. After shaking, the solutions were filtered and their absorbance was noted at 213 nm. The solubility of the Lercanidipine in every cyclodextrin solution was calculated and phase solubility diagram was drawn between the solubility of Lercanidipine and different concentrations of cyclodextrin. The stability constant of Lercanidipine cyclodextrin complex was calculated using Higuchi and Connor's equation.

$$K_{(1:1)} = \frac{\text{Slope}}{S_0\,(1) - \text{slope}}$$

S0 = Intrinsic solubility of Lercanidipinein aqueous complexation media (distilled water) "slope" was calculated from phase solubility diagram.

Solubility of Lercanidipine with different cyclodextrin concentrations are shown in Table 7.1 and phase solubility diagram is shown in figure 7.3

Preparation of Inclusion Complexes with B-Cyclodextrin:

Methods used in present work:

1) Physical mixture: Lercanidipine with β-CD in different molar ratios (i.e. 1:1M, 1:2M) were mixed in a mortar for about one hour with constant triturating, passed through sieve No. 80 and stored in desiccators over fused calcium chloride.

2) Kneading method: Lercanidipine with β-CD in different molar ratios (i.e. 1:1M, 1:2M) were taken. First cyclodextrin is added to the mortar, small quantity of 50 % ethanol is added while triturating to get slurry like consistency. Then slowly drug is incorporated into the slurry and triturating is further continued for one hour. Slurry

is then air dried for 24 h, pulverized and passed through sieve No. 80 and stored in desiccators over fused calcium chloride.

C) Solvent evaporation Method: Drug and cyclodextrin in different molar ratio are dissolved in a common solvent to get a clear solution. Mixed the both solutions than the clear solution was kept for stirring on a magnetic stirrer till all the solvent got evaporated. The mass obtained was dried at 50°C and further sieved No. 80 or 100 sieve.

Lercanidipine, β-Cyclodextrin Complexes.

Method	Drug to Carrier	Drug to Carrier ratio	Formulation Code
Physical Mixture	Lercanidipine: β-CD	1:1	LP1
	Lercanidipine: β-CD	1:2	LP2
Kneading Method	Lercanidipine: β-CD	1:1	LK1
	Lercanidipine: β-CD	1:2	LK2
Solvent evaporation method	Lercanidipine: β-CD	1:1	LS1
	Lercanidipine: β-CD	1:2	LS2

Evaluation of Lercanidipine Inclusion Complexes:

a) Physical Appearance: All batches of Lercanidipine inclusion complexes were evaluated for the color and appearance.

b) Drug Content Estimation

Estimation of Lercanidipine in the β-CD inclusion complex: Inclusion complexes prepared by physical mixture, kneading, and solvent evaporation methods were assayed for Lercanidipine content by dissolving a specific amount of the complexes (Drug Equivalent to 2mg) in methanol and analyzing for the Lercanidipine content spectrophotometrically at observed wavelength on a spectrophotometer.

c) Dissolution Characteristics

***In vitro* dissolution studies for Pure drug and its inclusion complexes:-** In vitro drug release studies for the pure Lercanidipine and prepared inclusion complexes were conducted in USP II paddle type dissolution apparatus in 500ml of medium at 37 ± 0.5^0C and at 50 rpm speed. The dissolution studies were carried out in 0.1N HCl. At

every interval 5 ml of sample was withdrawn from the dissolution medium and replaced with fresh medium to maintain the volume constant. After filtration and appropriate dilution, the sample solutions were analyzed at observed wavelegth by a UV – visible spectrophotometer. The amount of drug present in the samples was calculated.

Drug- Excipients Interaction studies by FTIR Spectroscopy.

A proper design and formulation of a dosage form requires considerations of the physical, chemical and biological characteristics of both drug and excipients used in fabrication of the product. Compatibility must be established between the active ingre-dient and other excipients to produce a stable, efficacious, attractive and safe product. If the excipient(s) are new and if no previous literature regarding the use of that particular excipient with an active ingredient is available, then compatibility studies are of paramount importance. Hence, before producing the actual formulation, compa-tibility of Lercanidipine with different polymers and other excipients was tested using the Fourier Transform Infrared Spectroscopy (FT-IR) technique.

FOURIER TRANSFORM INFRARED SPECTROSCOPY (FT-IR):

In order to check the integrity (Compatibility) of drug in the formulation,FT-IR spectra of the formulations along with the drug and other excipients were obtained and compared using Shimadzu FT-IR 8400 spectrophotometer. In the present study, Potassium bromide(KBr) pellet method was employed. The samples were thoroughly blended with dry powdered potassium bromide crystals. The mixture was compressed to form a disc. The disc was placed in the spectrophotometer and the spectrum was recorded.The FT-IR spectra of the formulations were compared with the FT-IR spectra of the pure drug and the polymers.

Compression of Lercanidipine-B-Cyclodextrin Inclusion Complexes into Immediate Release Tablets by Direct Compression Method:

After elucidation of best inclusion complex of drug with β-cyclodextrin which shows the most satisfactory invitro dissolution criteria and better solubility criteria, the particular complex was formulated as **Immediate Release Tablets of Lercanidipine β-cyclodextrin Inclusion Complex** by mixing it with selected excipients. In this present study, the best superdisintegrant among sodium starch glycolate (SSG), Crospovidone (CP), and croscarmellose sodium (CCS) were also screened out. Starlac selected as diluent, MCCPH101 as binder, talc as glidant and Magnesium stearate selected as lubricant.

COMPRESSION INTO TABLETS:

The prepared inclusion complex of drug and excipients were passed through sieve (#60) and mixed thoroughly. The drug and excipients mixture was finally compressed after lubricating with magnesium stearate for 10 min.

Formulation of Lercanidipine Inclusion Complexes Tablets

S. No	Ingredients	F1	F2	F3	F4	F5	F6	F7	F8
1	Lercanidipine	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**2**
2	Complexed drug (Lercanidipine: β-CD)	5.89	5.89	5.89	5.89	5.89	5.89	5.89	-
3	Starlac	68.51	66.01	66.01	66.01	63.51	61.01	58.51	67.6
4	MCCPH101	20	20	20	20	20	20	20	20
5	SSG	-	2.5						-
6	Crospovidone	-	-	2.5	-	5	7.5	10	-
7	CCS	-	-	-	2.5				4.8
8	Mag. Stearate	3.6	3.6	3.6	3.6	3.6	3.6	3.6	3.6
9	Talc	2	2	2	2	2	2	2	2
	Total Wt	100	100	100	100	100	100	100	100

*All values are expressed in mg/tablet

Results & Discussion:-

Formulation Studies for Inclusion Complexes

Phase solubility:

Phase solubility data of Lercanidipine

S.No	Concentration of BCD(mM)	Concentration of Lercanidipine (mM)
1	0	0.14
2	3	0.265
3	6	0.345
4	9	0.413
5	12	0.482
6	15	0.555



Phase solubility diagram of Lercanidipine-HCl

EVALUATION PARAMETERS

Drug content Estimation:

Drug content of complexes

S.No	Complexation method	Drug: cyclodextrin Ratio	Complex Code	Amount of drug present in 2mg Equivalent powder	%Drug content
1	Physical Mixture Method	1:1	**LP1**	2.01	102
		1:2	**LP2**	1.957	97.34
2	Kneading Method	1:1	**LK1**	2.045	101.3
		1:2	**LK2**	1.978	99.5
3	Solvent Evaporation Method	1:1	**LS1**	2.003	102.1
		1:2	**LS2**	2.05	103

In-vitro **Dissolution Characteristics**

Comparison of In-vitro dissolution data of all formulations (Pure drug-LS2)

Time (min)	% CDR						
	PURE DRUG	LP1	LP2	LK1	LK2	LS1	LS2

0	0	0	0	0	0	0	0
5	7.71	38.83	38.65	48.67	54.87	38.65	50.35
10	21.64	56.85	59.5	58.67	74.61	55.85	56.52
15	25.32	60.25	65.56	77.85	86.66	72.67	67.94
30	27.68	64.98	78.65	83.56	84.68	76.28	75.85
45	28.85	70.25	82.68	87.95	91.25	85.62	86.65
60	28.02	76.68	85.68	86.95	95.67	85.87	91.45



Dissolution Rate Data Profile graph of Lercanidipine and its complexes

IN-VITRO RELEASE KINETICS OF INCLUSION COMPLEXES:

Dissolution information could be explained by zero order and the first equation. Here, the kinematic values are recorded. The release of medication from the tablets is in a straight line indicates it.



Zero Order plots of Lercanidipine and Its Complexes in 0.1 N HCL

Comparison of R^2 value

FORMULATION CODE	Zero order kinetics	First order Kinetics
PURE DRUG	0.603	0.624
LP1	0.665	0.857
LP2	0.647	0.845
LK1	0.591	0.783
LK2	0.525	0.852
LS1	0.597	0.771
LS2	0.584	0.806

Evaluation Parameters for Immediate Release Tablets of Lercanidipine Cyclodextrin Complexes.

Evaluation of Pre-Compression Parameters of Tablet Blend:

Results of pre-compression parameters of tablet blend

Formulation code	F1	F2	F3	F4	F5	F6	F7
Angle of repose (Avg±S.D)	34.61±0.924	32.29± 0.394	32.55±0.597	32.21±0.602	33.46 ±0.5	**31.08±0.79**	32.47±0.39
Bulk density (Avg±S.D)	0.564±0.0096	0.552± 0.0068	0.564 ±0.005	0.571±0.0035	0.575 ± 0.007	**0.573 ±0.006**	0.564±0.0065
Tapped density (Avg±S.D)	0.628 ±0.005	0.634 ±0.0045	0.644 ±0.047	0.652 ±0.047	0.662 ± 0.004	**0.665 ±0.008**	0.624±0.0045
Compressibility index	13.21	12.93	12.54	11.83	12.64	**12.22**	13.20
Hausner's ratio	1.14	1.147	1.143	1.135	1.16	**1.14**	1.157

* Values are mean ± SD, n=3

Evaluation of Post-Compression parameters.

Results of Post-compression parameters

Formulation code	F1	F2	F3	F4	F5	F6	F7	F8
Hardness (avg ±S.D)	3.45±0.0576	3.24±0.0575	3.26±0.058	3.3±0.056	3.33±0.056	**3.23±0.114**	3.23±0.0576	3.26±0.058
Thickness (avg ±S.D)	2.514±0.0057	2.505±0.0057	2.513±0.0057	2.513±0.0057	2.513±0.0057	**2.513±0.0057**	2.503±0.0057	2.513±0.0057
Friability (avg ±S.D)	0.498±0.0996	0.232±0.0572	0.265±0.0577	0.068±0.00578	0.233±0.152	**0.295±0.24**	0.231±0.0572	0.264±0.0577
Weight variation (avg ±S.D)	100.54 ±2.49	100.15 ±1.774	99.94± 1.847	99.9 ±1.795	100.3 ±1.718	**99.8 ±1.607**	100.14 ±1.77	99.94 ±1.848
Wetting Time (Sec) (avg ±S.D	38±1.123433	24±0.3246	29±0.574303	29±0.126243	18±0.428646	**10±0.324323**	23±0.3246	27±0.674303
Disintegration time(avg ±S.D)	44±0.965446	27±0.624535	32±0.524236	34±0.764043	18±0.964245	**16±0.452677**	14±0.624535	20±0.524236
% Drug content (avg ±S.D)	101.34 ±008424	99.79± 0.065428	99.88± 0.041287	101.55 ±0.126423	100.63 ±0.102265	**100.63 ±0.102265**	99.96± 0.065428	99.9±0.081287

Values are mean ± SD, n=3

INVITRO-DISSOLUTION STUDIES

In-vitro Dissolution Studies of all Formulations

Time (Min)	FORMULATIONS							
	F1	F2	F3	F4	F5	F6	F7	F8
0	0	0	0	0	0	**0**	0	0
5	55.86	54.47	55.85	55.34	55.37	**55.05**	55.73	8.2
10	67.95	68.69	68.19	72.09	75.85	**75.18**	74.16	24.64
15	75.56	78.43	75.13	84.39	88.45	**86.89**	87.85	28.65
30	85.63	84.25	83. 74	85.25	95.28	**95.58**	96.14	39.05
45	87.35	91.13	88.32	88.18	94.65	**96.88**	95.25	42.13
60	94.57	95.25	96.63	94.62	95.36	**99.78**	98.26	46.24



Zero order release Plots for all formulations



First order release Plots for all formulations



Higuchi Square Root Time Dependent Plots for all formulations



Peppas double log Plots for all formulations

Curve fitting data analysis for all tablet formulations

FORMULATION	ZERO ORDER		FIRST ORDER			HIGUCHI		KORSEMEYER-PEPPAS	
	Slope (K)	R^2	Slope	(K)	R^2	Slope(K)	R^2	Slope(n)	R^2
F1	43.75	0.522	-0.016	1.725	0.818	22.64	0.78	0.194	0.865
F2	45.58	0.515	-0.0118	1.706	0.846	23.56	0.787	0.197	0.852
F3	44.48	0.518	-0.015	1.718	0.827	23.03	0.787	0.195	0.851
F4	43.97	0.525	-0.016	1.726	0.834	22.67	0.794	0.195	0.867
F5	47.03	0.377	-0.023	1.684	0.835	23.88	0.789	0.205	0.853
F6	**45.67**	**0.527**	**-0.028**	**1.742**	**0.936**	**23.59**	**0.799**	**0.212**	**0.859**
F7	45.21	0.509	-0.005	1.958	0.879	24.26	0.784	0.205	0.845
F8	9.505	0.825	-0.024	1.674	0.839	6.408	**0.946**	0.664	0.847

DISCUSSION

Lercanidipine β-Cyclodextrin Complexes

Lercandipine complex complexes were prepared by hand mixing with β-cyclodextrin, roller milling, and solvent extraction. Thus, the different complexes had different molar ratios of drug and cyclodextrin:one concentration, for instance, one-to-to-one or two-to-two. Prepared extracts were analysed using Fourier transform IR (FT-IR and the result was shown in Table 11. Tables 7 and 14 contain the results of all in vitro drug release and short-stability studies, respectively.

Without any residual gunkiness, the creams were clear and easy to scrape in each one direction The composition of the inclusion complexes was surprisingly constant

throughout the analysis. the percentage of the drug compounds varied between 98.53 to 102.53% with small standard deviations

PHASE SOLUBILITY STUDIES:

The AL type phase diagram for the cyclodextrin-Lercan conjugate is the following: Lercinine-beta has produced results shown good results in Figure 7.3 and Table 7.3. It is indicated by the phase diagram for Lercanipine in distil water and the β-CD system that the complex is linearly soluble. In compliance with Higuchi and Connor's procedure, the apparent curvature in an experiment, "Kc" was derived from the start position of the solubility curveIn a Lercid (β-CD) phase diagram, cyclodextrin forms a transition from a liquid to a solid, and Lercid solubility increases during this process. Classifying the solubility diagram as aβ-CD. As a function of the β-CD concentration, the aqueous solubility of Lercanipine increased in a linearly ascending manner (straight) path. The instability of Lercubipid-β inclusion (L-BIC).

***IN-VITRO* DISSOLUTION OF COMPLEXES**:

Pure Lercinium solution studies for in USP stand-mix (stand specimen) Lercin instrumentation was carried out in 900 ml of 0.1HCL in a USP paddle dissolution test system In Table 7, dissolution data for Lercid and Lercine-β are found.

The dissolution rate behaviour is demonstrated in Figure 7.5, where the results are depicted for LercanipiLan™ and prepared compositions obtained by Physical, Kneading, Solvent, and Solvent Evaporation methods. In all methods of dissolution testing, the reaction displayed a higher acceleration rate of progress than when compared to the rate of dissolution provided by pure drug data.

Lanipids are removed at an average rate of 79.106% in a period of 60 minutes when compared to an inclusion complex that contained only 28.08% of the Lercitranium. The various dissolution techniques were tested with two types of models, the zero order and the first order, to see which one had the best results. According to the first-order kinetic model, dissolution occurred at high rates of speed in the inclusion complexes. is found in Table 7.6 The results clearly indicated For the sake of continuity, the dissolution of Lercodipine is suggested. follows that of Creative Phrase The rate of dissolution was calculated using the varying y-axis scaling technique.from Lercaneptin is released in 75.68%, 84.68%, 87.96%, and 94.68% in 60 minutes, respectively, if used in a dissolution solution of 0.1HCL, respectively

Better results were seen with the use of Lercosonine solution. Inclusion complexes may exhibit higher dissolution rates due to better interaction with β-cyclodegen.

EVALUATION OF TABLETS:

For physical characteristics, all the Lercanidol Ketims preparations were classified, the cyclodextrin solutions (1:2 ratio) had their results measured from the Direct

compression was employed, and the source files were of high quality.Lanpicine tablets have a hardness of 3.23±0.00 kg and varies in the range of 3.46±0.46 to 3.46±0.46 kg The approximate time between completing a disintegration and the disintegration of tablets is 16 to 43 seconds For all three groups of the tablets, the friability and moisture variation and moisture-aging test times.

REFERENCES

1. Alfred Martin. Complexation and protein binding. Physical Pharmacy, 4th Edition, Waverly International, 428 St. Preston Street, Maryland, USA, 1993, 258-260.
2. Singh, A., Srinivasan, A.K., Chakrapani, L.N. and Kalaiselvi, P., 2019. LOX-1, the common therapeutic target in hypercholesterolemia: a new perspective of antiatherosclerotic action of aegeline. Oxidative medicine and cellular longevity, 2019.
3. Aguiar MM, Rodrigues JM, Silva Cunha A. Encapsulation of insulin-cyclodextrin complex in PLGA microspheres: a new approach for prolonged pulmonary insulin delivery. J Microencapsul. 2004; 21(5): 553-64.
4. Singh, A., Gowtham, S., Chakrapani, L.N., Ashokkumar, S., Kumar, S.K., Prema, V., Bhavani, R.D., Mohan, T. and Sathyamoorthy, Y.K., 2018. Aegeline vs Statin in the treatment of Hypercholesterolemia: A comprehensive study in rat model of liver steatosis. Functional Foods in Health and Disease, 8(1), pp.1-16.
5. Loftsson Thorsteinn, Marcus E Brewster. Pharmaceutical applications of cyclodextrins. Journal of Pharmaceutical Sciences, 85(10), 1996, 1017-1026.
6. K.P.R. Chowdary and A.M.S. Sudhakar Babu. "A Factorial Study to Evaluate the Individual and Combined Effects of β-Cyclodextrin and Tween 80 on the Solubility and Dissolution Rate of Aceclofenac". Asian Journal of Chemistry Vol.22, No. 6 (2010), 4281-4285.
7. Singh, A., Kumar, A. and Kalaiselvi, P., 2018. Aegeline, targets LOX1, the receptor for oxidized LDL to mitigate hypercholesterolemia: a new perspective in its anti-atherosclerotic action. Free Radical Biology and Medicine, 128, p.S41.
8. Singh, A., 2022. Role of microbial metabolites in cardiovascular and human health. In Microbiome, Immunity, Digestive Health and Nutrition (pp. 137-148). Academic Press.
9. Loftsson T, Magnusdottir A, Masson M, Sigurjonsdottir JF. Self-association and cyclodextrin solubilization of drugs, J Pharm Sci. 2002; 91(11):2307-2316.
10. Abhilasha, S., Narasimhan, C.L., Kumar, S.A., Kumar, S.N.K., Bhavani, R.D., Thangarajeswari, M., Prema, V. and Kalaiselvi, P., 2017. Ethanolic extract of

aegle marmelos mediates its hypocholesterolemic effect by retarding circulatory oxidized ldl formation via 12/15 lipoxygenase pathway.
11. Attama AA et al. Studies on diclofenac β-cyclodextrin inclusion complexes. Journal of Pharmaceutical Research, July 2004; 3(3): 47-49.
12. Singh, A., 2022. Role of microbial metabolites in cardiovascular and human health. In Microbiome, Immunity, Digestive Health and Nutrition (pp. 137-148). Academic Press.
13. Sunil Jambhekar, Casella R, Maher T. The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, HE β-CD and HPβ-CDs complexes. Inter.J.270, 2004,149-166.
14. Shiv Chandra Singh, A., Yu, A., Chang, B., Li, H., Rosenzweig, A. and Roh, J.D., 2021. Exercise Training Attenuates Activin Type II Receptor Signaling in the Aged Heart. Circulation, 144(Suppl_1), pp.A14259-A14259.
15. Chowdary KPR, Vijaya Srinivas. Effect of polyvinyl pyrrolidone on complexation and dissolution rate of β and HPβ-CD complexes of celecoxib. Ind.J.Pharm.Sci. Sept-oct. 2006, 631-634.
16. Roh, J., Hill, J.A., Singh, A., Valero-Muñoz, M. and Sam, F., 2022. Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models. Circulation Research, 130(12), pp.1906-1925.
17. Uppugalla S, Male U, Srinivasan P. Design and synthesis of heteroatoms doped carbon/polyaniline hybrid material for high performance electrode in supercapacitor application. Electrochimica Acta. 2014 Nov 10;146:242-8.
18. Male U, Uppugalla S, Srinivasan P. Effect of reduced graphene oxide–silica composite in polyaniline: electrode material for high-performance supercapacitor. Journal of Solid State Electrochemistry. 2015 Nov;19(11):3381-8.
19. Uppugalla S, Srinivasan P. High-performance supercapacitor coin cell: polyaniline and nitrogen, sulfur-doped activated carbon electrodes in aqueous electrolyte. Journal of Solid State Electrochemistry. 2019 Jan;23(1):295-306.
20. Uppugalla S, Srinivasan P. Polyaniline nanofibers and porous Ni [OH] 2 sheets coated carbon fabric for high performance super capacitor. Journal of Applied Polymer Science. 2019 Nov 5;136(41):48042.
21. Uppugalla S, Boddula R, Srinivasan P. Methyl triphenylphosphonium permanganate as a novel oxidant for aniline to polyaniline-manganese (II, IV) oxide: material for high performance pseudocapacitor. Journal of Solid State Electrochemistry. 2018 Feb;22(2):407-15.

22. Sanjula Baboota, Dhaliwal M, Kohli K., et.al. Inclusion complexation of rofecoxib with dimethyl β-cyclodextrin. Ind. J. of Pharm. Sci. March-April 2005, 226-229.
23. Boini, K.M., singh, A. and Koka, S.S., 2021. Gut Microbial Metabolite Trimethylamine N-oxide Enhances Endoplasmic Reticular Stress and Promotes Endothelial Dysfunction. Circulation, 144(Suppl_1), pp.A14071-A14071.
24. Hovgaard L, Bronsted H. Drug delivery studies in caco-2 monolayers. Absorption enhancer effects of cyclodextrins. Pharm Res. 1995; 12(9): 1328-1332.
25. Roh, J.D., Kitchen, R.R., Guseh, J.S., McNeill, J.N., Aid, M., Martinot, A.J., Yu, A., Platt, C., Rhee, J., Weber, B. and Trager, L.E., 2022. Plasma proteomics of COVID-19–associated cardiovascular complications: implications for pathophysiology and therapeutics. Basic to Translational Science, 7(5), pp.425-441MS. ZALAK R. PATEL, MRS. HETAL K. PATEL, MR. HARSH J. TRIVEDI, DR. KUNAL N. PATEL, and DR. BHAVESH S. NAYAK. "Enhancement of Solubility and Dissolution Properties of Lacidipine by Solid Dispersion". *International Journal of Pharmaceutics and Drug Analysis*, vol. 3, no. 5, May 2015, pp. 165-70, https://www.ijpda.com/index.php/journal/article/view/154.
26. Surya Prakash Gautam, Arun Kumar Gupta, Shahid Ud Din Wani, Neelesh Malviya, Tapsya Gautam, and Anil Kumar Sharma. "PAMAM Dendrimers Mediated Solubility Enhancement of Poorly Soluble Drugs: A Concise Review". *International Journal of Pharmaceutics and Drug Analysis*, vol. 3, no. 4, Apr. 2015, pp. 105-10, https://www.ijpda.com/index.php/journal/article/view/152.
27. Ankit Gupta, Mahesh Kumar Kataria, and Ajay Bilandi. "FORMULATION AND EVALUATION OF SOLID DISPERSION OF GLIPIZIDE FOR SOLUBILITY AND DISSOLUTION RATE ENHANCEMENT". *International Journal of Pharmaceutics and Drug Analysis*, vol. 2, no. 2, Feb. 2014, pp. 74-87, https://www.ijpda.com/index.php/journal/article/view/21.
28. MS. ZALAK R. PATEL, MRS. HETAL K. PATEL, MR. HARSH J. TRIVEDI, DR. KUNAL N. PATEL, and DR. BHAVESH S. NAYAK. "Enhancement of Solubility and Dissolution Properties of Lacidipine by Solid Dispersion". *International Journal of Pharmaceutics and Drug Analysis*, vol. 3, no. 5, May 2015, pp. 165-70, https://www.ijpda.com/index.php/journal/article/view/154.

29. Surya Prakash Gautam, Arun Kumar Gupta, Shahid Ud Din Wani, Neelesh Malviya, Tapsya Gautam, and Anil Kumar Sharma. "PAMAM Dendrimers Mediated Solubility Enhancement of Poorly Soluble Drugs: A Concise Review". *International Journal of Pharmaceutics and Drug Analysis*, vol. 3, no. 4, Apr. 2015, pp. 105-10, https://www.ijpda.com/index.php/journal/article/view/152.